title: Phenotypic fitness of primary endothelial cells cultured from patients with high cardiovascular risk or chronic kidney disease for vascular tissue engineering.
abstract: Vascular tissue engineering relies on the combination of patient-derived cells and biomaterials to create new vessels. For clinical application, data regarding the function and behavior of patient-derived cells are needed. We investigated cell growth and functional characteristics of human venous endothelial cells (HVECs) from coronary arterial bypass graft (CABG), chronic kidney disease (CKD), and control patients. HVECs were isolated from venous specimens that were obtained during elective surgical procedures by means of collagenase digestion. Gene expression, proliferation, migration, secretory functions, and thrombogenic characteristics were evaluated using high-throughput assays. A total of 48 cell batches (14 control, 19 CABG, and 15 CKD subjects) were assessed. Proliferation, population doubling times, and migration of HVECs derived from CABG and CKD patients did not differ from controls. Thrombomodulin expression was higher in CABG-HVECs compared with controls. HVEC-induced thrombin formation in plasma did not differ between groups, and the contact activation pathway was the major contributor to coagulation. Patient-derived HVECs were able to attach and survive on polycaprolactone scaffolds that were coated with fibrin. HVECs from cardiovascular-diseased and CKD patients showed comparable functional characteristics with HVECs derived from uncompromised patients. We, therefore, conclude that endothelial cells from aged patients with comorbidities can be safely used for isolation and in vitro expansion for vascular tissue engineering.
authors.affiliation: 1 Department of Physiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center , Maastricht, The Netherlands .
authors.forename: Irma L
authors.initials: IL
authors.lastname: Geenen
authors.forename: Sanne
authors.initials: S
authors.lastname: Verbruggen
authors.forename: Daniel G
authors.initials: DG
authors.lastname: Molin
authors.forename: Henri M
authors.initials: HM
authors.lastname: Spronk
authors.forename: Jos G
authors.initials: JG
authors.lastname: Maessen
authors.forename: Berry
authors.initials: B
authors.lastname: Meesters
authors.forename: Geert W
authors.initials: GW
authors.lastname: Schurink
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Post
mesh_terms: D000368:Aged; D001808:Blood Vessels / Q000473:pathology*; D002318:Cardiovascular Diseases / Q000473:pathology*; D002465:Cell Movement; D049109:Cell Proliferation; D002478:Cells, Cultured; D042783:Endothelial Cells / Q000473:pathology*; D011464:Epoprostenol / Q000378:metabolism; D005260:Female; D005455:Fluorescent Antibody Technique; D005786:Gene Expression Regulation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000378:metabolism; D010641:Phenotype; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000378:metabolism; D051436:Renal Insufficiency, Chronic / Q000473:pathology*; D012307:Risk Factors; D013927:Thrombosis / Q000473:pathology; D023822:Tissue Engineering / Q000379:methods*
chemical_list: D019408:Platelet Endothelial Cell Adhesion Molecule-1; D009569:Nitric Oxide; D011464:Epoprostenol